Hypermutated Gliomas Respond Poorly to Immunotherapy
- PMID: 32434948
- DOI: 10.1158/2159-8290.CD-NB2020-045
Hypermutated Gliomas Respond Poorly to Immunotherapy
Abstract
Unlike melanomas and colorectal cancers with a high tumor mutation burden, hypermutated gliomas generally do not respond to checkpoint blockade, a study concludes. Hypermutation shortens patient survival, and the results suggest that it occurs because of selective pressure from the chemotherapeutic temozolomide.
©2020 American Association for Cancer Research.
Comment on
-
Mechanisms and therapeutic implications of hypermutation in gliomas.Nature. 2020 Apr;580(7804):517-523. doi: 10.1038/s41586-020-2209-9. Epub 2020 Apr 15. Nature. 2020. PMID: 32322066 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
